Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

▤ Summary

Ensysce Biosciences announced that it enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study. The company is testing its MPAR overdose-protection technology, which is designed to reduce oral overdose risk while preserving therapeutic opioid exposure at prescribed doses. The program has already received Breakthrough Therapy designation from the FDA and is supported by the National Institute on Drug Abuse. Ensysce also said it plans to extend the platform into additional therapeutic areas such as amphetamines and methadone. This development matters because it advances a clinical pipeline that could eventually reshape how safer pain and addiction therapies are developed and commercialized.

▦ Linked Companies